Ascent Clinical Trial
Patients with Choroidal Neovascularization (CNV) a form of Wet Age-Related Macular Degeneration (AMD) (open for recruitment)
The purpose of this study is to evaluate a gene therapy product, RGX-314, for patients with choroidal neovascularization (CNV), a form of wet age-related macular degeneration (AMD). The purpose of this study is to evaluate the safety and efficacy of a single RGX-314 subretinal injection in participants with AMD compared to repeated intravitreal (IVT) injections. Review more details on this study at ClinicalTrials.gov.